Asset profile
N0877
Small molecule
Evidence outlook
Development stopped: Phase 3 study withdrawn before enrolling
The drug's registered studies are all terminated, withdrawn or suspended (NCT06608472: withdrawn before enrolling); none completed, so no evidence signal is assigned. Check the registry record for the sponsor's stated reason.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
60 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 8 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| N0877: this drug | Phase 3 | Small molecule | Angiotensin II receptor / Thiazide diuretic | ||
| Aprocitentan (Tryvio) | Approved | Small molecule | Endothelin receptor (ETA/ETB, dual) | ||
| Baxdrostat (Baxfendy) | Approved | Small molecule | Aldosterone synthase (CYP11B2) | ||
| Bosentan (Tracleer) | Approved | Small molecule | Endothelin receptor (ETA/ETB, dual) | ||
| Epoprostenol (Flolan) | Approved | Small molecule | IP receptor (prostacyclin pathway) | ||
| Nitric Oxide (INOmax) | Approved | Gas (inhaled) | Nitric oxide | ||
| Sacubitril / Valsartan (Entresto) | Approved | Small molecule | Neprilysin + Angiotensin II receptor (dual) | ||
| Treprostinil (Orenitram / Remodulin / Tyvaso) | Approved | Small molecule | IP receptor (prostacyclin pathway) | ||
| Treprostinil (Yutrepia, Liquidia) | Approved | Small molecule | IP receptor (prostacyclin pathway) | ||
| AD-209 | Phase 3 | Small molecule | Angiotensin II type 1 receptor / L-type calcium channel / Na-Cl cotransporter | ||
| AGSAVI | Phase 3 | Small molecule | Angiotensin II receptor / Calcium channel / Thiazide-like diuretic | ||
| AJU-C52 | Phase 3 | Small molecule | Angiotensin II receptor / Calcium channel / Thiazide-like diuretic | ||
| Ambrisentan (Letairis) | Phase 3 | Small molecule | Endothelin A receptor | ||
| C2402 | Phase 3 | Small molecule | — | ||
| CJ-30060 | Phase 3 | Small molecule | Angiotensin II receptor / Calcium channel / HMG-CoA reductase | ||
| CJ-30061 | Phase 3 | Small molecule | Angiotensin II receptor / Calcium channel / HMG-CoA reductase |
…and 45 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.